American Century Companies Inc. Sells 59,828 Shares of Halozyme Therapeutics, Inc. (HALO)

American Century Companies Inc. lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 23.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 199,617 shares of the biopharmaceutical company’s stock after selling 59,828 shares during the period. American Century Companies Inc.’s holdings in Halozyme Therapeutics were worth $3,627,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Halozyme Therapeutics by 5.7% in the 2nd quarter. BlackRock Inc. now owns 12,242,431 shares of the biopharmaceutical company’s stock worth $206,530,000 after purchasing an additional 659,763 shares during the period. Iridian Asset Management LLC CT lifted its stake in shares of Halozyme Therapeutics by 0.8% in the 2nd quarter. Iridian Asset Management LLC CT now owns 8,260,476 shares of the biopharmaceutical company’s stock worth $139,354,000 after purchasing an additional 68,098 shares during the period. Northern Trust Corp lifted its stake in shares of Halozyme Therapeutics by 11.1% in the 2nd quarter. Northern Trust Corp now owns 1,841,060 shares of the biopharmaceutical company’s stock worth $31,059,000 after purchasing an additional 183,480 shares during the period. Artisan Partners Limited Partnership lifted its stake in shares of Halozyme Therapeutics by 0.7% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,709,020 shares of the biopharmaceutical company’s stock worth $28,831,000 after purchasing an additional 11,260 shares during the period. Finally, MERIAN GLOBAL INVESTORS UK Ltd bought a new position in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $21,690,000. Hedge funds and other institutional investors own 85.52% of the company’s stock.

In other Halozyme Therapeutics news, major shareholder Randal J. Kirk sold 644,998 shares of the firm’s stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $18.08, for a total transaction of $11,661,563.84. Following the sale, the insider now owns 3,562,388 shares in the company, valued at approximately $64,407,975.04. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 16.80% of the stock is currently owned by company insiders.

Several equities analysts have recently weighed in on HALO shares. ValuEngine upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, October 3rd. BidaskClub cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a research note on Tuesday, November 13th. Cantor Fitzgerald set a $27.00 target price on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, October 31st. Finally, Piper Jaffray Companies initiated coverage on shares of Halozyme Therapeutics in a research note on Thursday, October 18th. They set a “hold” rating and a $17.00 target price on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $20.56.

NASDAQ HALO opened at $16.07 on Monday. Halozyme Therapeutics, Inc. has a 12 month low of $14.33 and a 12 month high of $21.48. The company has a market cap of $2.32 billion, a price-to-earnings ratio of 35.71 and a beta of 1.88. The company has a current ratio of 3.09, a quick ratio of 2.96 and a debt-to-equity ratio of 0.24.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. Halozyme Therapeutics had a net margin of 16.24% and a return on equity of 18.87%. The company had revenue of $25.60 million for the quarter, compared to analysts’ expectations of $30.42 million. During the same quarter last year, the business earned $0.02 EPS. The firm’s revenue was down 59.8% compared to the same quarter last year. As a group, analysts expect that Halozyme Therapeutics, Inc. will post -0.56 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.wkrb13.com/2018/11/26/american-century-companies-inc-sells-59828-shares-of-halozyme-therapeutics-inc-halo.html.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

See Also: Short Selling Stocks, A Beginner’s Guide

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply